‘A game changer’: TGA approves diabetes drug for CKD
The PBAC has already recommended listing empagliflozin for CKD.
The TGA has approved empagliflozin to prevent chronic kidney disease progression in adults regardless of diabetes status, in addition to standard care.
Under the expanded indication, doctors can write private scripts for daily empagliflozin 10mg (Jardiance) for patients with stage 2 or 3A chronic kidney disease with a urine albumin to creatinine ratio ≥30mg/g.
They can also prescribe the SGLT-2 inhibitor to patients with stages 3B, 4 or 5 chronic kidney disease (CKD) irrespective of urine albumin to creatinine ratio (ACR).
GP academic Associate Professor Ralph Audehm called it “a game changer” for treating renal disease.
